Mobile

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Update Il y a 4 ans
Reference: NCT00165659

Woman and Man

  • | Country :
  • Japan
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus* and SIB** as the primary efficacy measures. Safety of E2020 will also be evaluated. (*for overall evalution of clinical symtoms) (**for cognitive function test)

Inclusion criteria

  • Alzheimer Disease

Links